Education
About Us
Working with TipRanks
Follow Us
CARsgen Therapeutics Holdings Ltd. (HK:2171)
:2171
2171 Stock Chart & Stats
HK$14.89
HK$0.27(2.96%)
At close: 4:00 PM EST
HK$14.89
HK$0.27(2.96%)
Day’s Range― - ―
52-Week RangeHK$9.90 - HK$25.60
Previous CloseN/A
Volume4.65M
Average Volume (3M)1.98M
Market Cap
HK$8.71B
Enterprise ValueHK$6.44B
Total Cash (Recent Filing)HK$1.26B
Total Debt (Recent Filing)HK$140.85M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Mar 24, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding578,130,500
10 Day Avg. Volume1,760,508
30 Day Avg. Volume1,977,652
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)4.53
Price to Sales (P/S)121.30
P/FCF Ratio-11.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$29.08Price Target Upside95.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
In-house ManufacturingOwning research, process development and manufacturing for CAR‑T reduces dependency on external CDMOs, improves control of clinical/commercial supply chains, and supports long-term margin improvement and speed to market versus peers reliant on outsourced production.
Initial Commercialization TractionReturn of revenue in 2024 signals early commercialization or service income, indicating the business can monetize its platform. Durable significance: a revenue base enables learning, scaling, and eventual operating leverage if product uptake and payor pathways continue to develop.
Modest Financial LeverageLow debt relative to equity reduces short-term solvency risk and preserves flexibility to raise funding or pursue partnerships. For a cash‑consuming biotech, modest leverage lowers default risk and gives management options to weather R&D cycles without immediate refinancing pressure.
Bears Say
High Cash BurnSustained negative operating and free cash flow indicates ongoing reliance on external financing to fund R&D and operations. Over months this erodes runway, increases probability of dilutive equity raises or partnership payments, and constrains strategic choices until cash generation reverses.
Large Losses And Shrinking EquityMaterial net losses and a substantially reduced equity base reflect capital erosion over multiple years. This weakens the balance sheet cushion, raises dilution and financing risk, and limits the company’s ability to absorb clinical setbacks or finance scaling without onerous terms.
Cost Base Ahead Of ScaleOperating costs and R&D expenditures materially exceed current revenue, producing deeply negative margins. Structurally, the company needs meaningful revenue scale or sustained external funding to achieve profitability, making long-term viability sensitive to clinical and commercial execution.
CARsgen Therapeutics Holdings Ltd. News
2171 FAQ
What was CARsgen Therapeutics Holdings Ltd.’s price range in the past 12 months?
CARsgen Therapeutics Holdings Ltd. lowest stock price was HK$9.90 and its highest was HK$25.60 in the past 12 months.
What is CARsgen Therapeutics Holdings Ltd.’s market cap?
CARsgen Therapeutics Holdings Ltd.’s market cap is HK$8.71B.
When is CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date?
CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date is Mar 24, 2026 which is in 29 days.
How were CARsgen Therapeutics Holdings Ltd.’s earnings last quarter?
CARsgen Therapeutics Holdings Ltd. released its earnings results on Aug 15, 2025. The company reported -HK$0.158 earnings per share for the quarter, beating the consensus estimate of -HK$0.452 by HK$0.294.
Is CARsgen Therapeutics Holdings Ltd. overvalued?
According to Wall Street analysts CARsgen Therapeutics Holdings Ltd.’s price is currently Undervalued.
Does CARsgen Therapeutics Holdings Ltd. pay dividends?
CARsgen Therapeutics Holdings Ltd. does not currently pay dividends.
What is CARsgen Therapeutics Holdings Ltd.’s EPS estimate?
CARsgen Therapeutics Holdings Ltd.’s EPS estimate is -0.16.
How many shares outstanding does CARsgen Therapeutics Holdings Ltd. have?
CARsgen Therapeutics Holdings Ltd. has 578,130,500 shares outstanding.
What happened to CARsgen Therapeutics Holdings Ltd.’s price movement after its last earnings report?
CARsgen Therapeutics Holdings Ltd. reported an EPS of -HK$0.158 in its last earnings report, beating expectations of -HK$0.452. Following the earnings report the stock price went up 7.177%.
Which hedge fund is a major shareholder of CARsgen Therapeutics Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2171
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CARsgen Therapeutics Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
330.42%
12-Months-Change
Fundamentals
Return on Equity
-42.46%
Trailing 12-Months
Asset Growth
-26.61%
Trailing 12-Months
Company Description
CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.
2171 Stock 12 Month Forecast
Average Price Target
HK$29.08
▲(95.30% Upside)
Technical Analysis
Ascletis Pharma, Inc.
―
Everest Medicines Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Shanghai Haohai Biological Technology Co., Ltd. Class H
―
Options Prices
Currently, No data available
---